Media

Special Report: Racura Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential indications to explore in a clinical setting. Read full article here.

Proactive Investors covered Racura Oncology’s cardio-oncology strategy and the potential of RC220 to make anthracycline-based chemotherapy safer for patients. The article highlights progress in our international Phase 1 trial, our dual anticancer and cardioprotective approach, and recent IP advances supporting long-term value creation. Read the full article here.

Stockhead and The Australian included Racura Oncology in an ASX healthcare company quarterly results season wrap up, which highlights ongoing progress, including new discoveries and clinical trial updates to propel growth in FY26. The article covers Racura’s progress on clinical trials and the company’s discovery of a new way of patenting active chemical form of…

Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug. Dr Tillett explains how understanding the drug’s mechanism increases the probability of clinical success, allowing Racura to identify the cancer types most likely to respond, develop predictive biomarkers, and design…

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector and selects Racura Oncology as his ‘Powerplay’ stock pick of the week. Read the full article here.

Racura Oncology has uncovered a fresh chapter in its lead cancer program, identifying a novel mechanism of action for its (E,E)-bisantrene candidate. New data shows the compound binds to G4-DNA and RNA structures — genetic “switches” that regulate cancer-driving genes like MYC — setting it apart from doxorubicin-like chemotherapies that remain the backbone of treatment…

Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully about the company’s major scientific discovery, which has enabled a new composition of matter patent application for the (E,E)-bisantrene compound.  Dr Tillett explains why composition of matter patents are considered the gold standard in biotech IP, critical for securing future licensing and acquisition interest from…

Racura Oncology CEO Dr Daniel Tillett spoke with Proactive about the activation of the company’s first clinical site in Hong Kong for its Phase 1 RC220 trial in advanced solid tumours. Located at Queen Mary Hospital, this marks the start of patient enrolment in the region, with screening underway and the first patient expected to…

We are pleased to share another instalment of our “Inside Racura” video interview series, introducing Chief Medical Officer Dr Jose Iglesias, who joined the Racura Oncology team in May 2025. Dr Iglesias shares what first attracted him to the field of oncology and walks us through his distinguished 36-year career as a pharmaceutical executive. He…